G6PD and malaria: The 8-aminoquinoline tafenoquine was recently approved by the US Food and Drug Administration for the treatment of the dormant liver stage (hypnozoite) in P. vivax infection and for malaria chemoprophylaxis but can be used only in patients with normal glucose-6-phosphate dehydrogenase activity and is contraindicated in children, during pregnancy, and in lactating mothers with infants of deficient or unknown glucose-6-phosphate dehydrogenase status [9].